Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Sells 6,057 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 6,057 shares of the stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $3.94, for a total value of $23,864.58. Following the transaction, the general counsel now directly owns 151,125 shares in the company, valued at $595,432.50. The trade was a 3.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Health Catalyst Trading Up 1.5%

HCAT traded up $0.06 during trading on Monday, hitting $4.16. 535,112 shares of the stock were exchanged, compared to its average volume of 603,935. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The firm has a 50 day simple moving average of $3.95 and a 200 day simple moving average of $5.34. The firm has a market cap of $289.54 million, a price-to-earnings ratio of -3.08 and a beta of 1.53. Health Catalyst, Inc. has a 1 year low of $3.49 and a 1 year high of $9.24.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors have recently made changes to their positions in HCAT. Quantbot Technologies LP bought a new position in Health Catalyst during the 4th quarter worth about $29,000. Group One Trading LLC raised its stake in Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after buying an additional 2,260 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in Health Catalyst during the 4th quarter valued at $63,000. Focus Partners Wealth bought a new stake in Health Catalyst during the 1st quarter valued at $46,000. Finally, Stoneridge Investment Partners LLC purchased a new position in Health Catalyst in the fourth quarter valued at about $77,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HCAT. Evercore ISI lowered shares of Health Catalyst from an “outperform” rating to an “inline” rating in a research report on Wednesday, April 9th. Stephens cut their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Stifel Nicolaus increased their target price on Health Catalyst from $5.00 to $5.50 and gave the company a “hold” rating in a research report on Thursday, May 8th. Finally, KeyCorp lowered their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, April 16th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Health Catalyst has an average rating of “Moderate Buy” and an average price target of $8.00.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.